Skip to main content
Browse topics  Search all clinical trials

Clinical trials : lung-cancer

Showing 1 -6 of 6 results
This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery...

Monter Cancer Center | 450 Lakeville Road | Lake Success | NY 11042
This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, and multicenter study to evaluate the efficacy of rovalpituzumab tesirine as maintenance therapy following first-line platinum-based chemotherapy in patients with lung cancer...

Monter Cancer Center | 450 Lakeville Road | Lake Success | NY 11042
This randomized pilot clinical trial studies the side effects and best dose of naloxegol and to see how well it works in treating patients with stage IIIB-IV non-small cell lung cancer...

Monter Cancer Center | 450 Lakeville Road | Lake Success | NY 11042
The purpose of this study is to evaluate the safety and effectiveness of an experimental drug called atezolizumab when taken with chemotherapy compared to placebo (an inactive substance that looks like atezolizumab) plus chemotherapy...

Monter Cancer Center | 450 Lakeville Road | Lake Success | NY 11042
The purpose of this study is to evaluate the safety and tolerability of IV administration of VX15/2503 in combination with a fixed dose of avelumab in patients with advanced non-small cell lung cancer...

Monter Cancer Center | 450 Lakeville Road | Lake Success | NY 11042
The purpose of this study is to evaluate the efficacy and safety of pemetrexed plus platinum chemotherapy (carboplatin or cisplatin) with or without pembrolizumab (MK-3475; KEYTRUDA®) in the treatment of adults with the following types of tyrosine kinase inhibitor (TKI)-resistant, epidermal growth factor receptor (EGFR)-mutated, metastatic non-squamous non-small cell lung cancer (NSCLC) tumors: 1) TKI-failures (including osimertinib [TAGRISSO®] failure) with T790M-negative mutation tumors, 2) T790M-positive mutation tumors with prior exposure to osimertinib, and 3) first-line osimertinib failure regardless of T790M mutation status.

Center for Advanced Medicine (CFAM) | 450 Lakeville Road | Lake Success | NY 11042